Upper Respiratory Infections
Conditions
Keywords
Paracetamol, acetaminophen, phenylephrine, guaifenesin, syrup, URTI, productive cough
Brief summary
This is an open label, in-use study to assess the warming sensation, acceptability and local tolerability of paracetamol 500 mg + phenylephrine 10mg + Guaifenesin 200 mg syrup, given as a single dose in subjects suffering from symptoms of an upper respiratory tract infection. The purpose is to evaluate the acceptability concerning a warming sensation effect and its potential benefit in the target population. The primary objective is to assess the warming sensation caused by the excipient IFF flavor 316 282, in a syrup containing paracetamol 500 mg + phenylephrine 10mg + Guaifenesin 200 mg per 30 ml syrup. The syrup contains (0.15% w/v) warming flavor. The Secondary Objectives are to assess subject acceptability of the syrup and the safety and tolerability of the syrup. The study will be run in fifty-six (56) subjects suffering from symptoms of an upper respiratory tract infection (URTI) for 7 days or less, e.g. nasal congestion associated with colds and flu symptoms such as pain, headache and/or fever. Subjects must have one or more symptoms per category: 1. mild to moderate body pain, headache, fever or sore throat 2. nasal congestion (blocked nose) with or without rhinorrhea (runny nose) or sneezing 3. productive cough Adolescents will be included in the study population
Interventions
DRUGIFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin
Single dose syrup containing a warming flavor IFF flavor 316 282, in a syrup containing Paracetamol 500 mg + phenylephrine 10mg + Guaifenesin 200 mg per 30 ml syrup
Sponsors
Novartis Consumer Health
Novartis
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject must have one or more symptoms per category: * mild to moderate body pain, headache, fever or sore throat * nasal congestion (blocked nose) with or without rhinorrhea (runny nose) or sneezing * A productive cough
Exclusion criteria
* Baseline sore throat pain of severe intensity, e.g. rated as 3 on a 4-point ordinal scale (0=not present, 1= mild, 2=moderate, 3=severe) * Baseline dry cough of severe intensity, e.g. rated as 3 on a 4-point ordinal scale (0=not present, 1= mild, 2=moderate, 3=severe) * History of hypersensitivity to any of the study drugs and the listed excipients or to drugs of similar chemical classes * Subjects with allergic asthma. * Use of any inhaler, medicated confectionary, throat lozenges, throat pastilles, sprays, any products with demulcent properties such as chewing gums and boiled sweets or mints, in the 6 hours prior to dosing. * Use of any medication for sore throat containing a local anaesthetic within the 6 hours prior to dosing. * Use of paracetamol, any NSAID or any oral nasal decongestant within 6 hours prior to dosing. * Use of substances of abuse or antihistamines within 24 hours of dosing. * Drinking of tea, coffee or other caffeinated beverages 1 hour prior to dosing. * Suffering from hepatic or severe renal impairment, hypertension, hyperthyroidism, diabetes, heart disease or other acute or chronic medical condition that, in the opinion of the investigator, would put the subject at a higher risk or affect the conduct and/or the results of the study. * Use of any antidepressants, monoamine oxidase inhibitors or beta-blocking drugs in the 28 days prior to dosing * A history of alcohol abuse or subject admits to regular consumption of alcohol in excess of the recommended weekly limits of 21 units for females and 28 units for males. * Subject is a current smoker of ≥10 cigarettes per day (or reports equivalent smoking habits using other tobacco products). * Subject has smoked or chewed tobacco products within 12 hours of dosing. * History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Per 30 ml Syrup | 1 minutes | Intensity of warming sensation felt by subjects between predose to 1 minute postdose where 0= no warming sensation and 100= strongest possible warming sensation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Subject Acceptability of the Syrup | 1 hour | In response to the question How did you like the warming sensation you have experienced for this product?, the number of patients answering Like extremely or Like very much or Like moderately or Like slightly Possible responses are : Like extremely Like very much Like moderately Like slightly Neither like nor dislike Dislike slightly Dislike moderately Dislike very much Dislike extremely |
| Safety and Tolerability of the Syrup | 1 hour | Number of participants with adverse events. |
Countries
Canada
Participant flow
Recruitment details
Study Start/End Dates 09 Mar 2012 to 27 Apr 2012
Participants by arm
| Arm | Count |
|---|---|
| Upper Respiratory Tract Infection IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin : Single dose syrup containing a warming flavor IFF flavor 316 282, in a syrup containing Paracetamol 500 mg + phenylephrine 10mg + Guaifenesin 200 mg per 30 ml syrup | 51 |
| Total | 51 |
Baseline characteristics
| Characteristic | Upper Respiratory Tract Infection |
|---|---|
| Age, Categorical <=18 years | 1 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 50 Participants |
| Age Continuous | 32.0 years STANDARD_DEVIATION 12.65 |
| Region of Enrollment Canada | 51 participants |
| Sex: Female, Male Female | 26 Participants |
| Sex: Female, Male Male | 25 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 2 / 51 |
| serious Total, serious adverse events | 0 / 51 |
Outcome results
Primary
Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Per 30 ml Syrup
Intensity of warming sensation felt by subjects between predose to 1 minute postdose where 0= no warming sensation and 100= strongest possible warming sensation
Time frame: 1 minutes
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Upper Respiratory Tract Infection | Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Per 30 ml Syrup | 34.6 mm | Standard Deviation 27.96 |
Secondary
Safety and Tolerability of the Syrup
Number of participants with adverse events.
Time frame: 1 hour
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Upper Respiratory Tract Infection | Safety and Tolerability of the Syrup | 6 participants |
Secondary
Subject Acceptability of the Syrup
In response to the question How did you like the warming sensation you have experienced for this product?, the number of patients answering Like extremely or Like very much or Like moderately or Like slightly Possible responses are : Like extremely Like very much Like moderately Like slightly Neither like nor dislike Dislike slightly Dislike moderately Dislike very much Dislike extremely
Time frame: 1 hour
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Upper Respiratory Tract Infection | Subject Acceptability of the Syrup | 36 participants |